Immersive Technologies for Depression Care: Scoping Review.

BACKGROUND: Depression significantly impacts quality of life, affecting approximately 280 million people worldwide. However, only 16.5% of those affected receive treatment, indicating a substantial treatment gap. Immersive technologies (IMTs) such as virtual reality (VR) and augmented reality offer new avenues for treating depression by creating immersive environments for therapeutic interventions. Despite their potential, significant gaps exist in the current evidence regarding the design, implementation, and use of IMTs for depression care. OBJECTIVE: We aim to map the available evidence on IMT interventions targeting depression treatment. METHODS: This scoping review followed a methodological framework, and we systematically searched databases for studies on IMTs and depression. The focus was on randomized clinical trials involving adults and using IMTs. The selection and charting process involved multiple reviewers to minimize bias. RESULTS: The search identified 16 peer-reviewed articles, predominantly from Europe (n=10, 63%), with a notable emphasis on Poland (n=9, 56%), which contributed to more than half of the articles. Most of the studies (9/16, 56%) were conducted between 2020 and 2021. Regarding participant demographics, of the 16 articles, 5 (31%) exclusively involved female participants, and 7 (44%) featured participants whose mean or median age was >60 years. Regarding technical aspects, all studies focused on VR, with most using stand-alone VR headsets (14/16, 88%), and interventions typically ranging from 2 to 8 weeks, predominantly in hospital settings (11/16, 69%). Only 2 (13%) of the 16 studies mentioned using a specific VR design framework in planning their interventions. The most frequently used therapeutic approach was Ericksonian psychotherapy, used in 56% (9/16) of the studies. Notably, none of the articles reported using an implementation framework or identified barriers and enablers to implementation. CONCLUSIONS: This scoping review highlights the growing interest in using IMTs, particularly VR, for depression treatment but emphasizes the need for more inclusive and comprehensive research. Future studies should explore varied therapeutic approaches and cost-effectiveness as well as the inclusion of augmented reality to fully realize the potential of IMTs in mental health care.

Tuberculosis-HIV Co-Infection: Progress and Challenges After Two Decades of Global Antiretroviral Treatment Roll-Out / Coinfección tuberculosis-VIH: avances y retos 2 décadas después de la implementación del tratamiento antirretroviral a nivel global

Despite wide antiretroviral scale-up during the past two decades resulting in declining new infections and mortality globally, HIV-associated tuberculosis remains as a major public health concern. Tuberculosis is the leading HIV-associated opportunistic infection and the main cause of death globally and, particularly, in resource-limited settings. Several challenges exist regarding diagnosis, global implementation of latent tuberculosis treatment, management of active tuberculosis, delivery of optimal patient-centered TB and HIV prevention and care in high burden countries. In this article we review the advances on pathogenesis, diagnosis, and treatment after nearly two decades of global roll-out of antiretroviral therapy and discuss the current challenges for the global control of tuberculosis-HIV co-infection

A pesar de que el uso de antirretrovirales ha aumentado en uso y difusión durante las 2 últimas décadas, lo que ha resultado en la disminución de nuevas infecciones y de la mortalidad global, la tuberculosis asociada al VIH sigue siendo un importante problema de salud pública. La tuberculosis es la principal infección oportunista asociada al VIH y la principal causa de muerte a nivel mundial, particularmente en el marco de situaciones de recursos limitados. Existen varios retos con respecto al diagnóstico, la implementación global del tratamiento de la tuberculosis latente, el manejo de la tuberculosis activa, el proporcionar una prevención óptima de la tuberculosis y el VIH centrada en el paciente y la atención en países de alta carga. En este artículo revisamos los avances en la patogénesis, el diagnóstico y el tratamiento después de casi 2 décadas de implementación global de la terapia antirretroviral y comentamos los retos actuales para el control global de la coinfección tuberculosis-VIH

What Messages About Osteoporosis Are Offered in Spanish Videos on YouTube?

OBJECTIVE: The aim of this study was to determine the appropriateness of messages on osteoporosis in Spanish videos posted on YouTube. METHODS: YouTube Spanish language videos on osteoporosis were evaluated. The main variable was the presence of appropriate messages related to osteoporosis. The content was evaluated through a checklist based on available guidelines and reviewed by an expert (E.C.L.). The evaluation was performed twice independently for each video. A discussion of discordant messages was made with the expert. Other variables included were number of views, comments, "likes," and "dislikes"; the total duration of the video; and their source (health professionals and non-health professionals). Bivariate analysis between health professionals and non-health professionals were performed using the Mann-Whitney U and the χ tests. RESULTS: A total of 148 videos were reviewed. The median appropriate score for all videos was 5 (p25: 3, p75: 9) (maximum possible, 29 points). Seventy-three (49%) videos had a health professional as source, 124 (83.8%) mentioned at least one message in the definition area, 99 (66.9%) in the area of diagnosis, 99 (66.9%) in the area of recommendations, 43 (29.1%) in the area of treatment, and 5 (3.4%) in follow-up. The most frequent message was "risk of fracture" (68.9%). CONCLUSIONS: The content of osteoporosis information found in YouTube was generally incomplete and inaccurate. The content of these videos should include treatment and preventive strategies.

Tuberculosis-HIV Co-Infection: Progress and Challenges After Two Decades of Global Antiretroviral Treatment Roll-Out.

Despite wide antiretroviral scale-up during the past two decades resulting in declining new infections and mortality globally, HIV-associated tuberculosis remains as a major public health concern. Tuberculosis is the leading HIV-associated opportunistic infection and the main cause of death globally and, particularly, in resource-limited settings. Several challenges exist regarding diagnosis, global implementation of latent tuberculosis treatment, management of active tuberculosis, delivery of optimal patient-centered TB and HIV prevention and care in high burden countries. In this article we review the advances on pathogenesis, diagnosis, and treatment after nearly two decades of global roll-out of antiretroviral therapy and discuss the current challenges for the global control of tuberculosis-HIV co-infection.

Hernia diafragmática: diagnóstico prenatal y pronóstico / Diaphragmatic hernia: prenatal diagnosis and prognosis

La prevalencia de hernia diafragmática congénita es aproximadamente de 1 a 4 por cada 10,000 nacidos vivos. El defecto produce una alteración en el desarrollo del tejido pulmonar que está comprimido por las vísceras herniadas y, por consiguiente, una hipoplasia del lecho vascular pulmonar que puede ser causa de hipertensión pulmonar severa y/o persistencia del patrón de circulación fetal en las primeras horas después del nacimiento. La supervivencia es peor en pacientes cuya saturación de oxígeno preductal más alta registrada es inferior al 85% en las primeras 24 horas de vida. Además, la presión arterial pulmonar elevada (PpCO2) superior a 70 mmHg se asocia con una prognosis negativa. El presente caso es un ejemplo de que a pesar de un diagnóstico prenatal adecuado, la presencia de comorbilidades como: prematurez, sepsis, descompensación hemodinámica, hipertensión pulmonar afectan significativamente la probabilidad de supervivencia. Asi tambien, se sugiere una valoración con enfoque multidisciplinario en la fase prenatal para mejorar el manejo posnatal.

Congenital diaphragmatic hernia is approximately 1 to 4 per 10,000 live births. This defect affects the development of lung tissue that is compressed by herniated viscera. Consequently, pulmonary vascular hypoplasia causes severe pulmonary hypertension and/or fetal circulation pattern persistence in the first hours after birth. Overall survival is highly affecty when the highest values of preductal oxygen saturation are below 85% in the first 24 hours. Additionally, pulmonary high blood pressure (PpCO2) greater than 70 mmHg is associated with a negative prognosis. In this case, we showed that despite the fact appopiate prenatal diagnosis , the presenece of several complications such as prematurity, sepsis, hemodynamic decompensation, pulmonary hypertension contributes to reduce surival rate. Therefore, it is suggested to perform a multidisciplinary prenatal evaluation to improve postnatal management

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

OBJECTIVES: To assess plasma steady-state pharmacokinetics (PK) of rifampicin, isoniazid, saquinavir and ritonavir in HIV and tuberculosis (TB) co-infected patients, and investigate potential interactions between TB drugs and protease inhibitors (PIs). METHODS: Open-label, single-arm, sequential PK study including 22 patients with HIV infection and TB. During the first 2 months, patients received rifampicin, isoniazid and pyrazinamide, with or without ethambutol (first PK study, n = 22). Then patients stopped pyrazinamide and ethambutol and started once-daily antiretroviral therapy (ART) with didanosine, lamivudine, ritonavir (200 mg) and saquinavir (1600 mg) (second PK study, n = 18). Patients stopped all TB drugs after 9 months continuing the same ART (third PK study, n = 15). Differences between TB drug parameters in the first and second PK studies, and between PI parameters in the second and third PK studies were used to assess interactions. RESULTS: Rifampicin and isoniazid pharmacokinetics did not change substantially with saquinavir and ritonavir. A significant 39.5%, 34.9% and 48.7% reduction in median saquinavir AUC(0-24), C(max) and C(trough), respectively, was seen with rifampicin and isoniazid. Ritonavir AUC(0-24), C(max) and C(trough) decreased 42.5%, 49.6% and 64.3%, respectively, with rifampicin and isoniazid. CONCLUSIONS: There was a significant interaction between saquinavir, ritonavir and rifampicin, with reduction in median plasma concentrations of saquinavir and ritonavir. Saquinavir should be given with caution in patients receiving rifampicin. Twice-daily dosing or higher saquinavir doses in once-daily administration should be tested to obtain more appropriate plasma levels.

HIV and syphilis: when to perform a lumbar puncture.

OBJECTIVES: The objectives of this study were to determine predictive factors for neurosyphilis in HIV-infected patients with syphilis and optimize the use of lumbar puncture. STUDY DESIGN: The authors reviewed 112 cases of HIV-infected patients with syphilis who underwent a lumbar puncture. Diagnosis of neurosyphilis was based on a cerebrospinal fluid white blood cells count > or =20/microL, and/or a reactive cerebrospinal fluid-Venereal Disease Research Laboratory, and/or a positive intrathecal T. pallidum antibody (ITPA) index. RESULTS: Twenty-six of 112 had neurosyphilis. Neurologic manifestations and serum rapid plasma reagin (RPR) were associated with neurosyphilis (P = 0.036, P = 0.018, respectively). In multivariate analysis, log(2)RPR was still associated with neurosyphilis (P = 0.005). In patients without neurologic manifestations, the risk of neurosyphilis increases gradually with log(2)RPR. A serum RPR of 1/32 seems to be the best cutoff point to decide the performance or not of a lumbar puncture (sensitivity 100%, specificity 40%). CONCLUSION: In HIV-infected patients with syphilis, lumbar puncture could be restricted to those with neurologic manifestations or a serum RPR > or =1/32.

Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).

OBJECTIVES: To assess the efficacy and safety of a once-daily regimen with didanosine, lamivudine, saquinavir, and low-dose ritonavir in antiretroviral (ARV)-naive patients with tuberculosis treated with rifampin and the influence of rifampin on plasma trough concentration (Ctrough) of saquinavir. METHODS: Single-arm, prospective, multicenter, open-label pilot study, including 32 adult ARV-naive subjects with HIV infection and tuberculosis under standard treatment that included rifampin (600 mg q.d.) and isoniazid (300 mg q.d.). After 2 months of tuberculosis treatment, patients were started on once-daily ARV therapy, consisting of didanosine, lamivudine, ritonavir (200 mg), and saquinavir soft gel capsules (1600 mg). HIV RNA level, CD4 cell count, clinical and laboratory toxicity, and saquinavir Ctrough during and after antituberculosis therapy were analyzed. RESULTS: After 48 weeks of follow-up, 20 of 32 patients (62.5%; 95% CI: 45.8% to 79.2%) in the intent-to-treat population and 20 of 28 (71.4%; 95% CI: 54.4% to 88.4%) in the on-treatment population had an HIV RNA level <50 copies/mL. Treatment tolerance was acceptable in all patients except for 2 with biologic hepatic toxicity leading to discontinuation. Seven patients had virologic failure. In 10 patients (36%), saquinavir Ctrough was <0.05 microg/mL during tuberculosis therapy and 5 of them had virologic failure. The median saquinavir Ctrough was 44% lower (interquartile range: 19% to 71%) with coadministration of rifampin than without. CONCLUSION: The combination of didanosine, lamivudine, saquinavir, and ritonavir may be a useful treatment regimen for patients with tuberculosis in whom a once-daily protease inhibitor-containing regimen is considered indicated. Nevertheless, on the basis of pharmacokinetic profile the dose of 1600/200 mg of saquinavir/ritonavir cannot be recommended. Further studies with higher doses of saquinavir (2000 mg) boosted with ritonavir are warranted.